ZBH:NYSEZimmer Biomet Holdings, Inc. Analysis

Zimmer Biomet trades around $88.6, roughly 11% above its DCF-derived fair value of $67.6, suggesting limited upside in the near term despite a modest upside/downside estimate. The stock’s PE ratio of 22.9 sits slightly below the medical‑devices industry average of 24.8, and revenue is expanding at 9.3% YoY with strong 70% gross margin and 19.7% operating margin, indicating solid profitability. Dividend sustainability looks sound, with a 1.1% yield and a low 25% payout ratio, backed by healthy operating cash flow. Technical analysis shows the price above the 20‑day (85.5) and 50‑day (87.3) moving averages but still under the 200‑day average (92.9), a bullish MACD histogram, and a neutral RSI around 58, while volume is trending down, hinting at a cautious market. Recent news adds mixed signals: earnings disappointed shareholders, yet management announced an increased share‑repurchase program up to $1 billion and a quarterly dividend of $0.24, which could provide short‑term price support. Overall, the company balances growth prospects from its robotics and digital platforms against modest valuation premium and sector‑specific regulatory exposure.